{"disease":{"id":"primary-hypothyroidism-replacement-therapy","name":"Primary hypothyroidism - replacement therapy","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"levoxyl","indication_name":"Primary hypothyroidism - replacement therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levoxyl","generic_name":"Levothyroxine Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Thyroid receptor proteins attached to DNA","drug_class":"Thyroid hormone replacement","quality_score":10,"revenue":null,"mechanism":"Levothyroxine binds thyroid receptors in cell nuclei to activate gene transcription and protein synthesis."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"levoxyl","guideline_body":"FDA label","recommendation":"Levothyroxine sodium tablets are indicated as replacement therapy in primary hypothyroidism.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"levoxyl","guideline_body":"FDA label","recommendation":"Levothyroxine sodium tablets are indicated as replacement therapy in secondary hypothyroidism.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"levoxyl","guideline_body":"FDA label","recommendation":"Levothyroxine sodium tablets are indicated as replacement therapy in tertiary hypothyroidism.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"levoxyl","guideline_body":"FDA label","recommendation":"Levothyroxine sodium tablets are indicated as replacement therapy in congenital hypothyroidism.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"levoxyl","guideline_body":"FDA label","recommendation":"Levothyroxine sodium tablets are indicated as replacement therapy in acquired hypothyroidism.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"levoxyl","guideline_body":"FDA label","recommendation":"Levothyroxine sodium tablets are indicated as replacement therapy in hypothyroidism in adult patients.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"levoxyl","guideline_body":"FDA label","recommendation":"Levothyroxine sodium tablets are indicated as replacement therapy in hypothyroidism in pediatric patients.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"levoxyl","guideline_body":"FDA label","recommendation":"Levothyroxine sodium tablets are indicated as replacement therapy in hypothyroidism in neonates.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}